Kieckhefer Group LLC Acquires Shares of 1,900 Johnson & Johnson (NYSE:JNJ)

Kieckhefer Group LLC purchased a new stake in Johnson & Johnson (NYSE:JNJ) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 1,900 shares of the company’s stock, valued at approximately $275,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Hardin Capital Partners LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at about $778,000. SYM FINANCIAL Corp lifted its holdings in shares of Johnson & Johnson by 45.3% in the second quarter. SYM FINANCIAL Corp now owns 6,815 shares of the company’s stock valued at $996,000 after purchasing an additional 2,126 shares in the last quarter. Mcintyre Freedman & Flynn Investment Advisers Inc. increased its stake in shares of Johnson & Johnson by 0.8% during the 2nd quarter. Mcintyre Freedman & Flynn Investment Advisers Inc. now owns 12,291 shares of the company’s stock worth $1,796,000 after purchasing an additional 99 shares in the last quarter. Westover Capital Advisors LLC lifted its stake in Johnson & Johnson by 90.2% in the 2nd quarter. Westover Capital Advisors LLC now owns 5,983 shares of the company’s stock valued at $874,000 after buying an additional 2,837 shares in the last quarter. Finally, Schiavi & Co LLC grew its holdings in Johnson & Johnson by 11.4% during the 2nd quarter. Schiavi & Co LLC now owns 3,136 shares of the company’s stock valued at $458,000 after buying an additional 320 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Johnson & Johnson

In related news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on JNJ shares. StockNews.com downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 7th. Bank of America reaffirmed a “neutral” rating and issued a $166.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, December 10th. Guggenheim lifted their price target on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Wells Fargo & Company boosted their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Finally, Royal Bank of Canada increased their target price on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $174.71.

Johnson & Johnson Stock Up 0.4 %

Shares of NYSE:JNJ traded up $0.55 during midday trading on Monday, reaching $142.61. The company had a trading volume of 2,828,834 shares, compared to its average volume of 7,187,380. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The stock has a market capitalization of $343.35 billion, a P/E ratio of 20.64, a PEG ratio of 2.52 and a beta of 0.51. The stock’s fifty day moving average price is $149.67 and its 200-day moving average price is $156.11.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period last year, the firm earned $2.66 earnings per share. Equities research analysts expect that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.48%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.